The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.
Observers of the pharmaceutical industry got a surprise wake-up call on Sunday (7 June) with a report that AstraZeneca PLC had approached Gilead Sciences Inc. about a potential merger and spent the rest of the day weighing up the pros and cons of a deal that could create a healthcare giant worth over $230bn.
Bloomberg reported that AstraZeneca had made a preliminary approach to Gilead about a potential merger last month citing unnamed sources...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
